Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly
We don't own Eli Lilly exclusively for its potential Alzheimer's treatment. However, we still find Biogen's topline data to be very encouraging for Lilly.
Hollif
0
27
The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
Mike Blake | Reuters
